Corrias A, Pelosi U, Corona G B, Minelli R, Peri M, Corda R
Istituto di Clinica Pediatrica, Servizio di Allergologia ed Immunologia Infantile, Cagliari, Italia.
Pediatr Med Chir. 1989 Mar-Apr;11(2):161-3.
B2-agonists play a first-rate role in the exercise induced asthma (EIA) prevention for their capacity to modulate the bronchial tone. We studied the efficacy of a new B-sympathomimetic (Broxaterol) in 10 children (7 males and 3 females) with EIA in double blind vs salbutamol. During two consecutive days a basal treadmill incremental exercise test was made for determining bronchoconstriction rate (IB). Subsequently the test was repeated 30' and 150' after the drug's administration. The Broxaterol premedication determined, by comparison with the basal IB value, a mean difference of 11.9 after 30' (p less than 0.05) and 10.0 after 150' (p less than 0.01). No significant correlation was found comparing the salbutamol premedication. In conclusion our data confirms the Broxaterol efficacy in exercise-induced asthma prevention.
β2 激动剂因其调节支气管张力的能力,在运动诱发性哮喘(EIA)的预防中发挥着一流的作用。我们在 10 名患有 EIA 的儿童(7 名男性和 3 名女性)中,以双盲方式研究了一种新型β-拟交感神经药(溴沙特罗)与沙丁胺醇相比的疗效。在连续两天进行基础跑步机递增运动试验以确定支气管收缩率(IB)。随后在给药后 30 分钟和 150 分钟重复该试验。与基础 IB 值相比,溴沙特罗预处理在 30 分钟后平均差异为 11.9(p<0.05),在 150 分钟后为 10.0(p<0.01)。比较沙丁胺醇预处理时未发现显著相关性。总之,我们的数据证实了溴沙特罗在预防运动诱发性哮喘方面的疗效。